Do I need to exercise on Wegovy?

Yes — resistance training specifically. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Cardio is a bonus; resistance is the non-negotiable.

How fast do results show on GLP-1?

Appetite changes in 1-2 weeks. Visible weight loss usually starts in week 4-6. Significant fat loss accelerates in weeks 12-44 as the dose escalates.

Why am I not losing weight on Wegovy?

Most non-responders fall into 4 buckets: dose hasn't reached maintenance (2.4 mg), titration was interrupted, calorie intake creeps to match satiety, or a hormonal/medical confounder (hypothyroid, PCOS-with-insulin-resistance, sleep apnea). Talk to your prescriber if no measurable loss by week 16 at maintenance dose.

Can I build muscle on a GLP-1?

Yes — with deliberate resistance training and adequate protein. Without it, 25-40% of weight lost on GLP-1 comes from lean muscle. Lifting 2-3x/week + 1.2-1.6 g/kg ideal-body-weight protein preserves and can grow muscle while losing fat.

Can GLP-1 help with PCOS?

Yes — primarily via weight loss and improved insulin sensitivity. Smaller trials show improved ovulatory cycles and reduced androgen symptoms in women with PCOS. No GLP-1 is FDA-approved for PCOS; use is off-label and weight-driven.

Does GLP-1 work for type 1 diabetes?

No GLP-1 is FDA-approved for type 1 diabetes. Some endocrinologists prescribe semaglutide off-label as an insulin adjunct in T1D with obesity or insulin resistance, but evidence is limited and DKA risk during gastric-emptying changes requires careful monitoring.

NAFLD: Symptoms, Risks & GLP-1 Treatment

glpverdict

Subscribe Sign in

Editorial medical reviewFDA & peer-reviewed sourcesUpdated weeklyMedically reviewed content

GLP-1 evidence for NAFLD/MASH

Editorial grades summarizing study quality and convergence. How we grade.

Claim	Grade	Basis
Semaglutide resolves NASH without worsening fibrosis Source: NEJM, 2021 (opens in a new tab) Phase 2 RCT (n=320, 72 weeks); ~59% resolution vs 17% placebo at 0.4 mg	BModerate evidence	Phase 2 RCT (n=320, 72 weeks); ~59% resolution vs 17% placebo at 0.4 mg
Tirzepatide reduces liver fat in adults with T2D + steatosis Source: Lancet Diabetes & Endocrinology, 2022 (opens in a new tab) SURPASS-3 MRI sub-study showed liver-fat reduction dose-dependent	BModerate evidence	SURPASS-3 MRI sub-study showed liver-fat reduction dose-dependent
GLP-1 reverses advanced (F3-F4) fibrosis Some trial signal; phase 3 (ESSENCE) ongoing, results pending	CLimited evidence	Some trial signal; phase 3 (ESSENCE) ongoing, results pending
GLP-1 is FDA-approved for MASH No GLP-1 currently FDA-approved for MASH; resmetirom (Rezdiffra) is the only approved drug class	FNo evidence	No GLP-1 currently FDA-approved for MASH; resmetirom (Rezdiffra) is the only approved drug class

NAFLD / MASH(NAFLD)

Overview

Symptoms

Risk factors

Treatment options

GLP-1 evidence for NAFLD/MASH

Related GLP-1 medications

Mounjaro

Ozempic

Wegovy

Zepbound

Common questions readers ask

Sources